Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benedetta Bondi

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Biomedicines|February 27, 2026
New Insights in Respiratory DiseasesDiego Bagnasco, Benedetta Bondi
Current Opinion in Allergy and Clinical Immunology|December 2, 2025
Modifying the course of asthma: mechanisms and strategies for clinical remissionBenedetta Bondi, Diego Bagnasco, Fulvio Braido
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|March 21, 2026
Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 yearsMarco Bonavia, Benedetta Bondi, Diego Bagnasco, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 8, 2025
Comparative analysis of biologics' effects on lung function parameters in severe asthmaAngelica Tiotiu, Charles Pilette, Diego Bagnasco, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 10, 2024
SANI clinical remission definition: a useful tool in severe asthma managementGiorgio Walter Canonica, Diego Bagnasco, Benedetta Bondi, et al.
International Journal of Molecular Sciences|June 19, 2024
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target TherapyDiego Bagnasco, Laura De Ferrari, Benedetta Bondi, et al.
Expert Opinion on Drug Safety|May 11, 2026
Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populationsMarco Caminati, Claudia Gagliani, Benedetta Bondi, et al.
Respiratory Medicine|July 14, 2026
The PEACE-24 Study: Tezepelumab Improves Functional Exercise Capacity and Asthma Control in Severe AsthmaBenedetta Bondi, Fulvio Braido, Alessandro Pilo, et al.
Frontiers in Allergy|March 4, 2026
Silent invaders: the role of MPs on epithelium inflammation and damage in airway diseasesBenedetta Bondi, Stefania Nicola, Federico Di Marco, et al.
Biomedicines|May 25, 2024
Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with MepolizumabDiego Bagnasco, Benedetta Bondi, Marco Caminati, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Biomedicines|February 27, 2026
New Insights in Respiratory DiseasesDiego Bagnasco, Benedetta Bondi
Current Opinion in Allergy and Clinical Immunology|December 2, 2025
Modifying the course of asthma: mechanisms and strategies for clinical remissionBenedetta Bondi, Diego Bagnasco, Fulvio Braido
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|March 21, 2026
Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 yearsMarco Bonavia, Benedetta Bondi, Diego Bagnasco, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 8, 2025
Comparative analysis of biologics' effects on lung function parameters in severe asthmaAngelica Tiotiu, Charles Pilette, Diego Bagnasco, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 10, 2024
SANI clinical remission definition: a useful tool in severe asthma managementGiorgio Walter Canonica, Diego Bagnasco, Benedetta Bondi, et al.
International Journal of Molecular Sciences|June 19, 2024
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target TherapyDiego Bagnasco, Laura De Ferrari, Benedetta Bondi, et al.
Expert Opinion on Drug Safety|May 11, 2026
Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populationsMarco Caminati, Claudia Gagliani, Benedetta Bondi, et al.
Respiratory Medicine|July 14, 2026
The PEACE-24 Study: Tezepelumab Improves Functional Exercise Capacity and Asthma Control in Severe AsthmaBenedetta Bondi, Fulvio Braido, Alessandro Pilo, et al.
Frontiers in Allergy|March 4, 2026
Silent invaders: the role of MPs on epithelium inflammation and damage in airway diseasesBenedetta Bondi, Stefania Nicola, Federico Di Marco, et al.
Biomedicines|May 25, 2024
Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with MepolizumabDiego Bagnasco, Benedetta Bondi, Marco Caminati, et al.
Pageof 3